MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Cytokinetics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

39.78 -0.55

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

39.01

Max

40.45

Pagrindiniai rodikliai

By Trading Economics

Pajamos

11M

-150M

Pardavimai

16M

17M

Pelnas, tenkantis vienai akcijai

-1.26

Pelno marža

-886.276

Darbuotojai

498

EBITDA

13M

-125M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+116.74% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

4.5B

Ankstesnė atidarymo kaina

40.33

Ankstesnė uždarymo kaina

39.78

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Cytokinetics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-06-05 15:26; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

2025-04-11 09:30; UTC

Svarbiausios naujienos

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

2024-06-05 14:14; UTC

Įsigijimai, susijungimai, perėmimai

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Akcijų palyginimas

Kainos pokytis

Cytokinetics Inc Prognozė

Kainos tikslas

By TipRanks

116.74% į viršų

12 mėnesių prognozė

Vidutinis 82.36 USD  116.74%

Aukščiausias 120 USD

Žemiausias 54 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cytokinetics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

17

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

37.85 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.